-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$30.33115.26% Upside
Contineum Therapeutics, Inc. Class A Common Stock Frequently Asked Questions
-
What analysts cover Contineum Therapeutics, Inc. Class A Common Stock?
Contineum Therapeutics, Inc. Class A Common Stock has been rated by research analysts at Robert W. Baird, RBC Capital, Stifel Nicolaus in the past 90 days.